Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...

The nonprofit, The Endometriosis Collective, has included Schumer and Monroe in the feature-length documentary “End of the ...

Amid shifts in attitudes around family planning and contraception—and as the advent of telehealth outfits like Hims & Hers ...

More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...

After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new ...

AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...

A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing the drug's ability to normalize a key marker of disease progression for those with the rare liver disorder primary biliary ...

French drugmaker Sanofi is launching an artificial intelligence agent to help its field reps as the life sciences industry continues to ramp up its use of next-generation technology. The agent, called ...

As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a ...

Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease and related dementias (ADRDs). The Japanese drugmaker created its “Magnolia Meals at Home” ...